Reovirus: Rationale and clinical trial update

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 5, 2009, Pages 532-539

  Lal, R ^a   Harris, D ^b   Postel Vinay, S ^c   De Bono, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c INSTITUT CURIE   (France)

Author keywords

Biological agent; Chemotherapy; Clinical trial; Phase I; Radiotherapy; Ras; Reovirus

Indexed keywords

CARBOPLATIN; CD4 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; NEUTRALIZING ANTIBODY; OKT 8; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; PACLITAXEL; RAS PROTEIN; REOLYSIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILL; CLINICAL FEATURE; COLON CANCER; COLON TUMOR; COLORECTAL CANCER; COLORECTAL CARCINOMA; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOKALEMIA; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER METASTASIS; LOW DRUG DOSE; LUNG CANCER; LUNG METASTASIS; LYMPHOMA; MAMMALIAN ORTHOREOVIRUS; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; ONCOGENE RAS; OSTEOSARCOMA; OVARY CANCER; OVARY TUMOR; PROSTATE CANCER; RECURRENT CANCER; REOVIRUS; REVIEW; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; SWEATING; TREATMENT RESPONSE; VIROTHERAPY; VIRUS INFECTION; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RADIOTHERAPY; REOVIRIDAE;

ORTHOREOVIRUS;

EID: 70349932734     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Dock LL: The duty of this society in public work. 1904. NLN Publ (1991) (14-2410):319-321.
2. Csatary LK: Viruses in the treatment of cancer. Lancet (1971) 2(7728):825.
3. Sabin AB: Status of field trials with an orally administered, live attenuated poliovirus vaccine. J Am Med Assoc (1959) 171:863-868.
4. Rosen L: [Respiratory enterovirus and reovirus infections]. Arch Gesamte Virusforsch (1963) 13:272-280.
5. Schiff LA, Nibert ML, Tyler KL,: Orthoreoviruses and their replication. In: Field's Virology Volume1. Fields BN, Knipe DM, Howley PM (Eds), 5th Edition, Lippincott Williams & Wilkins, (2007):1853-1917.
6. Bodkin DK, Fields BN: Growth and survival of reovirus in intestinal tissue: Role of the L2 and S1 genes. J Virol (1989) 63(3):1188-1193.
7. Rubin DH, Kornstein MJ, Anderson AO: Reovirus serotype 1 intestinal infection: A novel replicative cycle with ileal disease. J Virol (1985) 53(2):391-398.
8. Kauffman RS, Wolf JL, Finberg R, Trier JS, Fields BN: The sigma 1 protein determines the extent of spread of reovirus from the gastrointestinal tract of mice. Virology (1983) 124(2): 403-410. (Pubitemid 13142203)
9. Rosen L, Evans HE, Spickard A: Reovirus infections in human volunteers. Am J Hyg (1963) 77:29-37.
10. Jackson GG, Muldoon RL, Cooper RS: Reovirus type 1 as an etiologic agent of the common cold. J Clin Invest (1961) 40: Abs 1051.
11. Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK: Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol (1987) 5(1):8-13. (Pubitemid 17125240)
12. Selb B, Weber B: A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods (1994) 47(1-2):15-25. (Pubitemid 24142003)
13. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: Usurpation of the Ras signalling pathway by reovirus. EMBO J (1998) 17(12):3351-3362. (Pubitemid 28279509)
14. Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev (2001) 81(1):153-208.
15. Duursma AM, Agami R: Ras interference as cancer therapy. Semin Cancer Biol (2003) 13(4):267-273.
16. Bos JL: RAS oncogenes in human cancer: A review. Cancer Res (1989) 49(17):4682-4689. (Pubitemid 19213607)
17. Norman K, Lee PW: Not all viruses are bad guys: The case for reovirus in cancer therapy. Drug Discov Today (2005) 10(12):847-855. (Pubitemid 40824739)
18. Stoeckel J, Hay JG: Drug evaluation: Reolysin - Wild-type reovirus as a cancer therapeutic. Curr Opin Mol Ther (2006) 8(3):249-260. (Pubitemid 43842396)
19. Smakman N, van den Wollenberg DJ, Borel Hinkes IH, Hoeben RC, Kranenburg O: Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colrectal carcinoma cells by reovirus T3D. J Virol (2005) 79(23):14981-14985. (Pubitemid 41636297)
20. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW: Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther (2007) 15(8):1522-1530.
21. Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science (1998) 282(5392):1332-1334.
22. R, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs (2009):doi:10.1007/s10637-009-9279.
23. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res (2003) 63(2):348-353. • First study to use systemic delivery of an oncolytic agent in conjunction with immune-suppressive drugs to effectively prolong animal survival. (Pubitemid 36152492)
24. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW et al: Reovirus therapy of lymphoid malignancies. Blood (2002) 100(12):4146-4153.
25. Kim M, Egan C, Alain T, Urbanski SJ, Lee PW, Forsyth PA, Johnston RN: Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene (2007) 6(28): 4124-4134.
26. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA: Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 16(5):689-699
27. Smakman N, van der Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel Rinkes IH, Kranenburg O: Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther (2006) 13(8):815-818. (Pubitemid 44100495)
28. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS: Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res (2005) 65(16):7045-7051. (Pubitemid 41161230)
29. Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, Selby P, Melcher A, Harrington K, Vile RG: Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide- mediated Treg modulation and interleukin-2 Clin Cancer Res (2009) 15(2):561-569.
30. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H et al: New 30 cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 14(1):259-269.
31. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A: Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 180(9):6018-6026.
32. Aghi M, Rabkin S, Martuza RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst (2006) 98(1):38-50. (Pubitemid 43057091)
33. Aghi M, Rabkin S: Viral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther (2005) 7(5):419-430. (Pubitemid 41489183)
34. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A: Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther (2005) 12(15):1198-1205.
35. Lunec A: EORTC-NCI-AACR - 16th Symposium. Molecular targets and cancer therapeutics. IDrugs (2004) 7(11):961-964.
36. Lane M, Fahey J, Besanceney C, Hamel N, Yu B, Thompson B, Coffey M, Wadler S: In vivo synergy between oncolytic reovirus and gemcitabine in Ras-mutated human HCT-116 xenografts. Proc Am Assoc Cancer Res (2007) 48:Abs 4812.
37. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F et al: Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 14(3): 912-923. (Pubitemid 351231176)
38. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA: Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 14(22):7358-7366.
39. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P et al: Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther (2008) 15(18):1257-1270.
40. Thirukkumaran CM, Luider JM, Stewart DA, Cheng T, Lupichak SM, Nodwell MJ, Russell JA, Auer IA, Morris DG: Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood (2003) 102(1):377-387. • Results indicate the ex vivo use of an unattenuated oncolytic virus represents an attractive purging strategy for autologous stem cell transplantations. (Pubitemid 36759680)
41. Loree TR, Strong EW: Significance of positive margins in oral cavity squamous carcinoma. Am J Surg (1990) 160(4):410-414.
42. Mechor B, Seikaly H, Wong K, Chau J, Uwiera R, Harris JR: Reovirus salvage of positive resection margin: A novel treatment adjunct. J Otolaryngology (2006) 35(2):97-101. • As RAS mutations or other defects in related genes affecting downstream portions of the pathway that convey susceptibility to reovirus are common in squamous cell head and neck cancer, reovirus treatment could have considerable clinical applications. (Pubitemid 43671673)
43. Atiyah RA, Krespi YP, Hidvegi D, Sisson GA Sr: The mechanical spread of viable tumor during surgery. Otolaryngol Head Neck Surg (1986) 94(3):278-281. (Pubitemid 16075550)
44. Machtay M, Perch S, Markiewicz D, Thaler E, Chalian A, Goldberg A, Kligerman M, Weinstein G: Combined surgery and postoperative radiotherapy for carcinoma of the base of tongue: Analysis of treatment outcome and prognostic value of margin status. Head Neck (1997) 19(6):494-499. (Pubitemid 27349668)
45. Fang FM, Leung SW, Huang CC, Liu YT, Wang CJ, Chen HC, Sun LM, Huang DT: Combined-modality therapy for squamous carcinoma of the buccal mucosa: Treatment results and prognostic factors. Head Neck (1997) 19(6):506-512. (Pubitemid 27349670)
46. Collins S: Decreasing the risk of implantation of cancer cells intraoperatively. Laryngoscope (1993) 103(7):825-827.
47. Fortner JG: Inadvertent spread of cancer at surgery. J Surg Oncol (1993) 53(3):191-196.
48. Brookes JT, Seikaly H, Lim T, Wong KK, Harris JR, Moore RB: Reovirus salvage of squamous cell cancer-contaminated wounds. J Otolaryngology (2005) 34(1):32-37. (Pubitemid 40797355)
49. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS: A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 14(21):7127-7137. • Results suggest that intravenous reovirus therapy may represent a feasible treatment modality for metastatic cancer in humans.
50. Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M et al: A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther (2008) 16(3):627-632.
51. Harris D, Vidal L, Melcher A, Newbold K, Anthony A, Karavasilis V, Agarawal R, White C, Twigger K, Coffey M, Mettinger K et al: A phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type reovirus (Reolysin) in combination with radiation in patients with advanced malignancies. Proc Mol Targets Cancer Therapeutics (2007):Abs B81.
52. Morris D, Forsyth P, Paterson A: A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol (2002) 21(1):Abs 92.
53. R/paclitaxel and carboplatin trial. Press Release (2007): May 29.
54. R/docetaxel trial. Press Release (2007): July 23.
55. Oncolytics Biotech Inc: Oncolytics Biotech Inc proceeds to initiate US phase II sarcoma clinical trial. Press Release (2007): April 11.
56. R/cyclophosphamide trial. Press Release (2008): May 09.